Mezzion Pharma Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 03:04 am EST
Share
Mezzion Pharma Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was KRW 2,157.28 million compared to net loss of KRW 1,600.29 million a year ago. Basic earnings per share from continuing operations was KRW 81 compared to basic loss per share from continuing operations of KRW 60 a year ago. Diluted earnings per share from continuing operations was KRW 69 compared to diluted loss per share from continuing operations of KRW 60 a year ago. Basic earnings per share was KRW 81 compared to basic loss per share of KRW 60 a year ago. Diluted earnings per share was KRW 69.
For the nine months, negative sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net loss was KRW 18,187.33 million compared to KRW 7,113.43 million a year ago. Basic loss per share from continuing operations was KRW 681 compared to KRW 267 a year ago. Diluted loss per share from continuing operations was KRW 681 compared to KRW 267 a year ago. Basic loss per share was KRW 681 compared to KRW 267 a year ago. Diluted loss per share was KRW 613.
Mezzion Pharma Co., Ltd. is a Korea-based company engaged in the pharmaceutical business. The Company focuses on development and manufacture of remedies for erectile dysfunction and benign prostatic hyperplasia. In addition, the Company engages in the development of remedies for portal hypertension (PH), pulmonary arterial hypertension (PAH), overactive bladder (OAB), chronic obstructive pulmonary disease (COPD) and others. The Company has sighed licensing contract with overseas partners, including Warner in America, Valenta in Russia, Nycomed in Mexico and Dr.Falk in Europe. On April 22, 2013, the Company changed its name from Dong-A Pharmtech Co., Ltd. to Mezzion Pharma Co., Ltd.
MEZZION PHARMA CO.,LTD. 
